Chaoyuan (Charlie) Kuang, MD, PhD, is Assistant Professor of Oncology, Medicine and Molecular Pharmacology at Montefiore Einstein and Co-Leader of GI Cancer Clinical and Translational Research at Montefiore Einstein Comprehensive Cancer Center (MECCC). His research focuses on the preclinical and clinical development of novel therapies for colorectal cancer. His clinical focus is on the treatment of patients with colorectal and other gastrointestinal malignancies, as well as the enrollment of patients into clinical trials.

Through preclinical research of colorectal cancer using patient-derived and mouse models of cancer, Dr. Kuang’s research focuses on the discovery of novel therapies and biomarkers of cancer and scientific development of early phase trials for cancer. He is the principal investigator of the MECCC Biobank and collaborates with several scientific and clinical investigators at Montefiore Einstein. He serves as co-chair of the MECCC Excellence in Career Enrichment Leadership Committee and is a member of the Montefiore Einstein MSTP Steering Committee. He has shared his research through peer-reviewed journals, book chapters, seminars, and oral and poster presentations.

I am an Assistant Professor at the Montefiore Einstein Comprehensive Cancer Center at the Albert Einstein College of Medicine in Bronx, New York. I specialize in gastrointestinal malignancies. Since my early training, I have been interested in studying early onset colorectal cancer (EO-CRC). My research has focused on the design and development retrospective study using Surveillance, Epidemiology, and End Results Program (SEER) Database to understand treatment strategies and its effects on survival for young patients with colorectal cancer.

Additionally, I devoted much of my time to studying disparities in cancer care for racial and ethnic minorities, leading to multiple studies with national and international collaborations. Since becoming an Assistant Professor, I have been an institutional principal investigator (PI) on industry-led clinical trials in colorectal cancer, working with the research staff to ensure that the studies are running according to the expected timeframe and accrual goals are being met. I also designed, wrote, developed, and conducted The HOLA COVID-19 Study: An International Effort to Determine How COVID-19 Has Impacted Oncology Practices in Latin America.